Monoclonal Antibody Therapy Drug Market on Trajectory Towards $140 Billion - Seite 3

Pfizer Inc. (NYSE:PFE) recently stated it had acquired a 15% equity interest stake in privately-held gene therapy company Vivet, and secured an exclusive option to acquire all outstanding shares of the company. Pfizer openly said it will look to collaborate with Vivet on the development of VTX-801, which Is a proprietary treatment for the life-threatening liver disorder, Wilson disease.

Looking to secure its second multiple myeloma nod in newly diagnosed patients in the US, Johnson & Johnson (NYSE:JNJ) isn't winning many friends with England's cost watchdogs. The National Institute for Health and Care Excellence (NICE) agreed to back a multiple myeloma combo that includes J&J's Darzalex, Takeda's Velcade, and corticosteroid dexamethasone in patients who have received one previous treatment. However, the Cancer Drugs Fund (CDF) has only agreed to cover the first use and not routine use.

A top player in the Global Research Antibodies Market, Thermo Fisher Scientific Inc. (NYSE: TMO) is a world's largest maker of scientific and laboratory equipment. In 2013 the company acquired biotechnology company Life Technologies for approximately US$13.6 billion. The acquisition catapulted  Thermo Fisher, to the forefront of the field of personalized medicine. In 2017 they acquired leading global manufacturer of drugs for clinical trials – Patheon N.V., for $5.2 billion. Patheon's drug manufacturing capabilities under its arsenal of services enabled Thermo Fisher to grab a bigger slice of the contract development and manufacturing market.

For a FREE research report on ImmunoPrecise Antibodies Ltd. (TSX.V:IPA) (OTC:IPATF), visit www.microsmallcap.com. 

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.